CompletedNCT04841785

RECOVAC - Long Term Efficacy and Safety of COVID-19 (SARS-CoV-2) Vaccination in Kidney Disease Patients

Studying Severe acute respiratory syndrome

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
University Medical Center Groningen
Principal Investigator
Jan-Stephan F Sanders, MD PhD
University Medical Center Groningen
Intervention
mailer-based finger-prick(diagnostic_test)
Enrollment
4868 target
Eligibility
18 years · All sexes
Timeline
20212023

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04841785 on ClinicalTrials.gov

Other trials for Severe acute respiratory syndrome

Additional recruiting or active studies for the same condition.

See all trials for Severe acute respiratory syndrome

← Back to all trials